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Introduction: Common features of autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia include
candidiasis, hypoparathyroidism and hypoadrenalism. The initial manifestation of autoimmune
polyendocrinopathy-candidiasis-ectodermal dysplasia may be autoimmune hepatitis, keratoconjunctivitis,
frequent fever with or without a rash, chronic diarrhea, or different combinations of these with or without
oral candidiasis.
Case presentation: We discuss a profoundly affected 2.9-year-old Caucasian girl of Western European
descent with a dramatic response to immunosuppression (initially azathioprine and oral steroids, and then
subsequently mycophenolate mofetil monotherapy). At four years of follow-up, her response to
mycophenolate mofetil is excellent.
Conclusion: The clinical features of autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia may
continue for years before some of the more common components appear. In such cases, it may be life-saving to
diagnose autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia and commence therapy with
immunosuppressive agents. The response of our patient to immunosuppression with mycophenolate mofetil has
been dramatic. It is possible that other patients with this condition might also benefit from immunosuppression.
Keywords: APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia), APS (autoimmune
polyendocrinopathy syndrome), Autoimmunity, Immunosuppression, EndocrinopathiesIntroduction
The autoimmune regulator (AIRE) gene, on chromo-
some 21, expresses self-antigens in the thymus and med-
iates negative selection of self-reactive T-cells [1].
Autoimmune polyendocrinopathy-candidiasis-ectodermal
dysplasia (APECED), or autoimmune polyendocrinopathy
syndrome type I, occurs due to loss of function of AIRE,
with resultant loss of thymic tolerance to self-antigens [1].
Common features of APECED include candidiasis,
hypoparathyroidism and adrenal insufficiency [2]. The
initial manifestation of APECED may be autoimmune* Correspondence: clodagh.ogorman@ul.ie
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distribution, and reproduction in any mediumhepatitis, keratoconjunctivitis, frequent fever with or
without a rash, chronic diarrhea, or different combina-
tions of these with or without oral candidiasis. This
clinical picture may continue for years before the ap-
pearance of the more common components [2]. In such
cases, it may be life-saving to diagnose APECED and
commence therapy with immunosuppressive agents.
The literature on therapeutic options for severe mani-
festations of this rare condition is scarce. Some data
suggest that a younger age at presentation is associated
with increased disease severity, although the authors do
not specify how young [2]. We discuss a profoundly
affected young patient with a dramatic response to im-
munosuppression using mycophenolate mofetil (MMF).tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 2 Vitiligo (red arrows) (seen under Wood’s lamp).
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A 2-year-old girl of non-consanguineous Caucasian par-
ents of Western European descent, developed the follow-
ing clinical features over 12 months: hypoparathyroidism
with hypocalcemia and borderline high serum phosphate
(parathyroid hormone 20ng/L, normal 10 to 65; total
calcium 1.98mmol/L, normal 2.2 to 2.6; phosphate
2.1mmol/L, normal 1.6 to 2.1); mucocutaneous candid-
iasis (Figure 1); keratoconjunctivitis; sialoadenitis; viti-
ligo (Figure 2); urticaria-like rash (Figure 3); and
alopecia. At age 2.9 years, she required intensive care
admission and ventilation for aspiration pneumonia
and significant respiratory compromise. During this ad-
mission, severe hypoparathyroidism with significant
hypocalcemia was managed with high doses of intra-
venous and subsequently oral calcium and calcitriol.
APECED was confirmed following identification of a
homozygous 13 base pair deletion on AIRE exon 8;
both parents were heterozygous carriers.
Previously, she had been investigated and treated for
several episodes of aspiration pneumonia, frequent diar-
rhea, intermittent urticaria-like eruptions (Figure 3) with
lymphocytic vasculitis on biopsy and frequent fevers of
unknown origin. Between diarrheal illnesses, she had se-
vere constipation, including a partial small bowel ob-
struction at 1.3 years old.
Laboratory evaluation revealed: normal thyroid func-
tion tests; positive anti-thyroid peroxidase antibodies;
normal glucocorticoid function following adrenal stimu-
lation; positive anti-adrenal and anti-21-hydroxylase
antibodies; normal electrolytes and mineralocorticoid
function; intercurrent stress hyperglycemia; positive
anti-glutamic acid decarboxylase antibodies but negative
islet cell and anti-insulin antibodies. While ventilated,
Candida albicans was cultured from her endotracheal
tube; C. albicans and organic food material were isolated
following closed lung biopsy.Figure 1 Mucocutaneous candidiasis (red arrow).Her diarrhea worsened, and became associated with
deterioration of her hypoparathyroidism and hypocalce-
mia requiring prolonged parenteral calcium. Hypocalce-
mia was marked after discontinuing parenteral calcium
for even a few hours. She then developed mineralocor-
ticoid insufficiency, worsening sicca symptoms, and re-
current life-threatening respiratory tract infections.
After seven months of hospitalization, immunosup-
pression was commenced, first using high dose oral
prednisone (two mg/kg), then azathioprine (1.5mg/kg).
Calcium and diarrhea stabilized somewhat. However,
repeated attempts to wean maintenance steroids failed
due to exacerbations of diarrhea and hypocalcemia.
Therefore, immunosuppression was changed to MMF
monotherapy (900mg/m2). Prednisone was weaned suc-
cessfully to physiological maintenance doses, and contin-
ued at these doses.
Her clinical response to immunosuppression was dra-
matic. Intravenous calcium was discontinued after one
week; diarrhea began to resolve (Figure 4). Within oneFigure 3 Urticaria-like eruption (red arrows).
Figure 4 Graph of calcium intake, serum calcium and diarrhea over time, including response to immunosuppression. Ca; Calcium.
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oral calcium and calcitriol supplements. Linear growth,
salivation, lacrimation and repigmentation of her eye-
lashes improved.
She is now seven years old, height 110.7cm (3rd centile)
and weight 19.2kg (16th centile). She still has frequent
episodes of fever, although not consistently related to
infections. She has had documented throat and lower re-
spiratory tract infections, but these have responded well
to antibiotics without further support. Her lung function
testing is normal. MMF was titrated to achieve target
area under the curve of 40 to 60mg/hour/L. Notably,
when MMF is held for even two to three days (for ex-
ample during febrile illnesses), despite doubling or trip-
ling steroids for stress dosing, diarrhea deteriorates, she
becomes hypocalcemic, requiring increased calcium and
calcitriol supplementation (Figure 4).
Discussion
This case highlights a dramatic response of a young pa-
tient with APECED to immunosuppression with MMF
therapy as a steroid-sparing immunosuppressant, despiteTable 1 Summary of case reports of use of immunosuppressio
Year of publication Authors of manuscript Age of patient at in
immunosuppressio
1997 Padeh et al. [4] 15
1999 Ward et al. [5] 13
2006 Perheentupa [2] Various ages
2006 Ulinski et al. [7] 6
2007 Bakrac et al. [8] 33
This manuscript O’Gorman et al. 2.9
MMF; mycophenolate mofetil.an initial poor response to azathioprine. To the best of
our knowledge, our patient with APECED is the young-
est treated with immunosuppression to date; see Table 1
for manuscripts describing immunosuppression for
patients with APECED. The initial clinical manifesta-
tions of APECED may be autoimmune hepatitis, kerato-
conjunctivitis, frequent fever with or without a rash,
chronic diarrhea, or different combinations of these with
or without oral candidiasis [2]. This clinical picture may
continue for years before some of the more common
components appear. In such cases, it may be life-saving
to diagnose APECED and commence therapy with im-
munosuppressive agents [2]. For atypical cases, a simple
diagnostic test for APECED (autoantibodies against
interferon omega) is available [3].
In a 13-year-old patient diagnosed with APECED at
age 2.5 years, the successful use of steroids, followed by
three years of methotrexate maintenance has been
described [4]. When immunosuppression was started,
she had mucocutaneous candidiasis, alopecia, hypopara-
thyroidism, adrenal insufficiency and pancreatic insuffi-




Methylprednisolone for induction; methotrexate for
maintenance
Cyclosporin A
Prednisone and azathioprine combination
Prednisone and azathioprine; then plus cyclosporin A;
then changed to prednisone, MMF and tacrolimus
Prednisone and cyclosporin A; then MMF
Methylprednisolone; then prednisone and azathioprine;
then MMF
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months of immunosuppression [5]. This patient’s disease
is now controlled with MMF (Personal communication,
Cheri Deal, 2009). In 2002, Perheentupa discussed pred-
nisone and azathioprine for chronic hepatitis in a patient
with APECED and referred to glucocorticoids and either
azathioprine or methotrexate in several patients with
diarrhea [6]. Immunosuppression with prednisone and
azathioprine, and subsequently with cyclosporin A, was
reported following renal transplantation for chronic
interstitial nephritis in a patient with APECED. Im-
munosuppression was unsuccessful with azathioprine
but successful with cyclosporin A [7]. A patient with
APECED with pure red cell aplasia responding well to
MMF has also been described [8].
Two cautions regarding the use of immunosuppres-
sion for patients with APECED are reported [6]:
increased risk of candidiasis-related malignancies, such
as oral malignancies; and increased risk of the progres-
sion from localized to systemic candidiasis. Six patients
with APECED with oral or esophageal squamous cell
carcinomas have been described; the youngest was 29
years old and immunosuppressed for six years; the
others were not immunosuppressed [6]. It is unclear if
candida-related malignancies in APECED are related to
APECED or to its treatments [9]. It is also important to
note that immunosuppression for a patient with
APECED is really a decision tailored to the specific
details of an individual patient. In this case, significant
consideration and discussion among many health
professionals and the patient’s family occurred before
immunosuppression was started. Furthermore, any
decision to initiate immunosuppression should be ac-
companied by a definite plan for monitoring the re-
sponse to this new therapy.
After four years of follow-up, we have not observed sig-
nificant side-effects of immunosuppression in our young
patient. When she presents with febrile or infectious ill-
nesses, MMF is temporarily discontinued but, within 2–3
days, diarrhea increases and she develops hypocalcemia,
requiring increased enteral calcium and calcitriol supple-
mentation. For our patient, inflammatory markers, diar-
rhea, required doses of calcium supplementation and
weight gain are good markers of disease activity. Abnor-
mal swallowing and silent aspirations are not recognized
features of APECED and it is possible that our patient’s
respiratory symptoms may represent new autoimmune-
related APECED manifestations or another co-incident
disease process. Chronic diarrhea is a recognized feature
of APECED [6]. Our patient’s diarrhea may represent
autoimmune gastrointestinal disease, but this was not bi-
opsy proven before immunosuppression. Obstipation is a
recognized manifestation [10] and our patient has not
had bowel obstructions since MMF was commenced.Conclusions
Immunosuppression is well tolerated and has resulted in
dramatic improvement in our young patient with severe
manifestations of APECED. We suggest that early initi-
ation of immunosuppression, with appropriate monitor-
ing, is an acceptable therapy for patients severely affected
with APECED and that failure of one immunosuppres-
sive agent does not infer failure of others.
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